Nuvectis Pharma Inc

NASDAQ:NVCTUnited States

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is developing two drug candidates: NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator, which is in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP800 activates the GCN2 kinase inducing inhibition of cap-dependent protein translation and activation of the integrated stress response leading to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is undergoing a Phase 1a dose escalation study. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers.

Contact Information

Headquarters

1 Bridge Plaza, Suite 275FORT LEE, NJ, United States 07024

Phone

360-837-7232

Fax

302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer, Co-Founder

Ron Bentsur

Co-Founder, Executive Vice President, Chief Development and Operations Officer

Shay Shemesh

Executive Vice President, Chief Scientific and Business Office, Co-Founder

Enrique Poradosu

Vice President - Finance

Michael Carson

Independent Director

Kenneth Hoberman